MAXHEALTH - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.5
| Stock Code | MAXHEALTH | Market Cap | 95,276 Cr. | Current Price | 979 ₹ | High / Low | 1,314 ₹ |
| Stock P/E | 135 | Book Value | 87.3 ₹ | Dividend Yield | 0.15 % | ROCE | 12.5 % |
| ROE | 9.45 % | Face Value | 10.0 ₹ | DMA 50 | 1,043 ₹ | DMA 200 | 1,088 ₹ |
| Chg in FII Hold | -1.25 % | Chg in DII Hold | 1.17 % | PAT Qtr | 200 Cr. | PAT Prev Qtr | 160 Cr. |
| RSI | 32.8 | MACD | -16.9 | Volume | 29,73,107 | Avg Vol 1Wk | 49,74,219 |
| Low price | 934 ₹ | High price | 1,314 ₹ | PEG Ratio | 4.29 | Debt to equity | 0.08 |
| 52w Index | 11.9 % | Qtr Profit Var | 5.45 % | EPS | 7.10 ₹ | Industry PE | 43.5 |
📊 Financial Overview
- Revenue & Profitability: PAT rose from 160 Cr. to 200 Cr. QoQ, showing growth. EPS at 7.10 ₹ is modest relative to valuation.
- Margins & Returns: ROE at 9.45% and ROCE at 12.5% are moderate, reflecting average capital efficiency.
- Debt & Liquidity: Debt-to-equity ratio of 0.08 indicates low leverage, enhancing financial stability.
- Cash Flow: Profit growth supports reinvestment, though margins remain modest compared to valuation multiples.
💹 Valuation Metrics
- P/E Ratio: 135 vs Industry PE of 43.5 → Extremely overvalued.
- P/B Ratio: ~11.2 (Price 979 ₹ / Book Value 87.3 ₹) → Expensive relative to assets.
- PEG Ratio: 4.29 → Indicates growth is priced at a steep premium.
- Intrinsic Value: Current price appears significantly above fair value zone.
🏢 Business Model & Competitive Advantage
Max Healthcare operates in hospital and healthcare services, with strong presence in North India. Its competitive advantage lies in brand recognition, infrastructure, and growing demand for healthcare services. However, valuations are stretched relative to fundamentals.
📈 Entry Zone & Long-Term Guidance
Technically, RSI at 32.8 and negative MACD suggest oversold conditions. A better entry zone would be 940–970 ₹ (near support levels). Long-term holding is advisable only if earnings growth sustains and valuations normalize.
✅ Positive
- Quarterly PAT growth (200 Cr. vs 160 Cr.).
- Low debt-to-equity ratio (0.08).
- DII holdings increased (+1.17%), showing domestic confidence.
⚠️ Limitation
- High P/E (135) and P/B (~11.2) ratios.
- PEG ratio (4.29) indicates expensive growth pricing.
- ROE and ROCE are moderate compared to valuation multiples.
📉 Company Negative News
- FII holdings decreased (-1.25%), showing reduced foreign confidence.
- Valuation significantly above industry average.
📈 Company Positive News
- Quarterly PAT improved QoQ.
- DII accumulation signals domestic support.
🏭 Industry
The healthcare industry benefits from rising demand for hospital services, medical infrastructure, and preventive care. Industry PE at 43.5 highlights Max Healthcare’s premium valuation relative to peers.
🔎 Conclusion
Max Healthcare is fundamentally stable with steady profit growth and low debt, but valuations are stretched. While domestic investor confidence is a positive, foreign sentiment has weakened. Accumulation near 940–970 ₹ is recommended for long-term holding, contingent on sustained earnings growth and normalization of valuation multiples.